Clinton E. Canal

Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD)

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Trial of Psilocybin versus Escitalopram for Depression

Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants

Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex

Potential Therapeutic Effects of Psilocybin

Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers

Serotonin, But Not N -Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD)

Psychedelics

LTP maintenance and its protein synthesis-dependence

Interaction of 5-HT2A and 5-HT2C Receptors in R(−)-2,5-Dimethoxy-4-iodoamphetamine-Elicited Head Twitch Behavior in Mice

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice

Beyond extinction: erasing human fear responses and preventing the return of fear

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling

Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences

Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species

Characterization of the head-twitch response induced by hallucinogens in mice

The neural basis of psychedelic action

Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice

Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Animal Models of Serotonergic Psychedelics

N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT₂Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues

Head‐twitch response in rodents induced by the hallucinogen 2,5‐dimethoxy‐4‐iodoamphetamine: a comprehensive history, a re‐evaluation of mechanisms, and its utility as a model

About Sleep's Role in Memory

Retrieval induces reconsolidation of fear extinction memory

How Does Mindfulness Meditation Work? Proposing Mechanisms of Action From a Conceptual and Neural Perspective

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Prescribed drugs containing nitrogen heterocycles: an overview

“Selective” serotonin 5-HT2A receptor antagonists

RNA editing of the serotonin 2C receptor and expression of Gα_qprotein: genetic mouse models do not support a role for regulation or compensation

Drug discovery targeting human 5-HT2C receptors: Residues S3.36 and Y7.43 impact ligand—Binding pocket structure via hydrogen bond formation

Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model

The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen

Different temporal profiles of amnesia after intra-hippocampus and intra-amygdala infusions of anisomycin.

Amnesia produced by altered release of neurotransmitters after intraamygdala injections of a protein synthesis inhibitor

Classics in Chemical Neuroscience: Aripiprazole